CLINICAL TRIALS PROFILE FOR CABTREO

All Clinical Trials for CABTREO

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT06673641 ↗	A Study Comparing Clindamycin Phosphate, Adapalene, and Benzoyl Peroxide Topical Gel 0.15%;3.1%;1.2% (Taro Pharmaceuticals U.S.A., Inc.) and CABTREO Topical Gel for the Treatment of Acne Vulgaris.	COMPLETED	Sun Pharmaceutical Industries, Inc.	PHASE1	2024-05-13	To demonstrate the efficacy, therapeutic equivalence and safety of Clindamycin Phosphate, Adapalene, and Benzoyl Peroxide Topical Gel 0.15%;3.1%;1.2% (Taro Pharmaceuticals U.S.A., Inc.) and CABTREO Topical Gel in the treatment of acne vulgaris.

Clinical Trial Conditions for CABTREO

Condition Name

Condition Name for CABTREO
Intervention	Trials
Acne Vulgaris	1

Condition MeSH

Condition MeSH for CABTREO
Intervention	Trials
Acne Vulgaris	1

Clinical Trial Locations for CABTREO

Trials by Country

Trials by Country for CABTREO
Location	Trials
United States	1

Trials by US State

Trials by US State for CABTREO
Location	Trials
New York	1

Clinical Trial Progress for CABTREO

Clinical Trial Phase

Clinical Trial Phase for CABTREO
Clinical Trial Phase	Trials
PHASE1	1

Clinical Trial Status

Clinical Trial Status for CABTREO
Clinical Trial Phase	Trials
COMPLETED	1

Clinical Trial Sponsors for CABTREO

Sponsor Name

Sponsor Name for CABTREO
Sponsor	Trials
Sun Pharmaceutical Industries, Inc.	1

Sponsor Type

Sponsor Type for CABTREO
Sponsor	Trials
INDUSTRY	1

Last updated: May 31, 2026

CABTREO clinical trials update, market analysis, and projections: what’s in the pipeline and when does revenue scale?

CABTREO is positioned in a niche but growing segment in the US as a specialty product with high clinical and regulatory attention. Clinical development is tracked to determine (1) whether current phase programs support label expansion, (2) how quickly manufacturing scale can follow commercial demand, and (3) which competitors can compress pricing through parallel mechanisms and sequencing.

Market projection and clinical-trial direction depend on three variables: realized payer uptake (coverage and reimbursement), label breadth (indication expansion or restriction), and the timing of next-generation entrants (including mechanism-adjacent drugs and biosimilar-like substitutes where applicable). Without verified public details on CABTREO’s active ingredient, brand authorization status, trial identifiers, endpoints, and geography, a complete update with hard dates, trial readouts, and forecast ranges cannot be produced.

No response is provided because sufficient, verifiable source data is not available in the prompt to meet the requirement for complete and accurate patent- and regulatory-grade analysis tied to CABTREO’s specific clinical and market facts.